personal scheduler Hamburg 2013 - Main Site Press Release 2013 Call for Abstracts General Information Programme Overview Letter from the President Keynote Lectures Main Sessions NEW - Free Paper Session Instructional Courses World Retina Day Retinal Detachment Course Uveitis Course Other Symposia Surgical Skills Training Courses
hamburg banner

Levels of the angiogenic biomarker endocan are elevated in proliferative diabetic retinopathy vitreous and correlate with VEGF levels

Session Details

Session Title: Vascular Diseases I

Session Date/Time: Friday 27/09/2013 | 08:00-10:00

Paper Time: 08:40

Venue: Hall C (Level 1)

First Author: A.Abu El Asrar SAUDI ARABIA

Co Author(s):                  

Abstract Details

Purpose:

Endocan, a proteoglycan specifically secreted by endothelial cells, is a marker of angiogenesis and endothelial cell activation in response to proangiogenic signals. The aim of this study was to measure the levels of endocan in the vitreous fluid from patients with proliferative diabetic retinopathy (PDR) and to correlate its levels with clinical disease activity and the levels of the angiogenic biomarkers vascular endothelial growth factor (VEGF), soluble vascular endothelial-cadherin (sVE-cadherin) and soluble endoglin (sEng).

Setting:

Case-control study

Methods:

Vitreous samples from 44 PDR and 29 nondiabetic patients were studied by enzyme-linked immunosorbent assay.

Results:

Endocan, VEGF, sVE-cadherin and sEng levels were significantly higher in PDR patients than in nondiabetic patients (p<0.001; p=0.002; p<0.001; p=0.001, respectively). Endocan levels were significantly higher in patients with active PDR than in patients with inactive PDR and nondiabetic patients (p<0.001). There were significant correlations between endocan levels and the levels of VEGF (r=0.574, p<0.001) and the levels of sVE-cadherin (r=0.498, p<0.001).

Conclusions:

Endocan could be a new biomarker of endothelial cell activation and angiogenesis in PDR and may be a useful therapeutic target.

Back to Freepaper Session
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy